MicroRNA-377 predicts poor clinical outcome of gastric cancer and induces tumorigenesis by targeting multiple tumor-suppressor genes

Wen,Xu; Wu,Jian-Qiu; Peng,Wei; Feng,Ji-Feng; Tang,Jin-Hai

doi:10.3892/or.2015.3981

MicroRNA-377 predicts poor clinical outcome of gastric cancer and induces tumorigenesis by targeting multiple tumor-suppressor genes

Authors:
- Xu Wen
- Jian-Qiu Wu
- Wei Peng
- Ji-Feng Feng
- Jin-Hai Tang
View Affiliations

Affiliations: Department of General Surgery, Nanjing Medical University Affiliated Cancer Hospital, Cancer Institute of Jiangsu Province, Nanjing 210009, P.R. China, Department of Medical Oncology, Nanjing Medical University Affiliated Cancer Hospital, Cancer Institute of Jiangsu Province, Nanjing 210009, P.R. China
Published online on: May 15, 2015 https://doi.org/10.3892/or.2015.3981
Pages: 203-210

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Gastric cancer (GC) is a major cause of cancer mortality worldwide. MicroRNAs are evolutionally conserved small non-coding RNAs that are critical for the regulation of gene expression. The aberrant expression of microRNA (miRNA) is involved in tumorigenesis and prognosis. In the present study, the clinical significance of miR-377 was assessed using RT‑qPCR and MTT assay. The results showed that the expression of miR-377 was upregulated in GC compared with normal gastric tissues, and its expression level was increased in GC cell lines compared with normal gastric cells. In addition, there was a significant association between miR-377 expression and clinicopathological characteristics, in particular distant metastasis, TNM stage and early recurrence. GC patients with a higher miR-377 expression showed significantly poorer overall survival (OR) and shorter time to recurrence than those with a lower miR-377 expression. The Cox regression analysis identified miR-377 overexpression as an independent prognostic factor for GC. Overexpression of miR-377 in MKN-45 GC cells significantly promoted cell proliferation, whereas the suppression of miR-377 inhibited these effects. Furthermore, miR-377 downregulated p53, PTEN and TIMP1 expression by directly targeting the 3'-untranslated region of these target genes. Collectively, miR-377 potentially served as a new molecular predictive biomarker of GC tumorigenesis and prognosis, which may be useful in targeted therapy and the prognosis of GC patients.

View Figures

View References

1	Gibson CJ, Britton KA, Miller AL and Loscalzo J: Clinical problem-solving. Out of the blue. N Engl J Med. 370:1742–1748. 2014.PubMed/NCBI
2	Wu WKK, Lee CW, Cho CH, Fan D, Wu K, Yu J and Sung JJ: MicroRNA dysregulation in gastric cancer: A new player enters the game. Oncogene. 29:5761–5771. 2010. View Article : Google Scholar : PubMed/NCBI
3	Song JH and Meltzer SJ: MicroRNAs in pathogenesis, diagnosis, and treatment of gastroesophageal cancers. Gastroenterology. 143:35–47. 2012. View Article : Google Scholar : PubMed/NCBI
4	Lin X, Yang M, Xia T and Guo J: Increased expression of long noncoding RNA ABHD11-AS1 in gastric cancer and its clinical significance. Med Oncol. 31:422014. View Article : Google Scholar : PubMed/NCBI
5	Shen L, Shan YS, Hu HM, Price TJ, Sirohi B, Yeh KH, Yang YH, Sano T, Yang HK, Zhang X, et al: Management of gastric cancer in Asia: Resource-stratified guidelines. Lancet Oncol. 14:e535–e547. 2013. View Article : Google Scholar : PubMed/NCBI
6	Chitwood DH and Timmermans MC: Small RNAs are on the move. Nature. 467:415–419. 2010. View Article : Google Scholar : PubMed/NCBI
7	Morris KV, Chan SW, Jacobsen SE and Looney DJ: Small interfering RNA-induced transcriptional gene silencing in human cells. Science. 305:1289–1292. 2004. View Article : Google Scholar : PubMed/NCBI
8	Cai H, Yuan Y, Hao YF, Guo TK, Wei X and Zhang YM: Plasma microRNAs serve as novel potential biomarkers for early detection of gastric cancer. Med Oncol. 30:4522013. View Article : Google Scholar : PubMed/NCBI
9	Yu X, Luo L, Wu Y, Yu X, Liu Y, Yu X, Zhao X, Zhang X, Cui L, Ye G, et al: Gastric juice miR-129 as a potential biomarker for screening gastric cancer. Med Oncol. 30:3652013. View Article : Google Scholar : PubMed/NCBI
10	Wang Q, Wang Y, Minto AW, Wang J, Shi Q, Li X and Quigg RJ: MicroRNA-377 is up-regulated and can lead to increased fibronectin production in diabetic nephropathy. FAsEB J. 22:4126–4135. 2008. View Article : Google Scholar : PubMed/NCBI
11	Wen ZL, Huang W, Feng YL, Wang Y, Liang J, Cai W, Kang K, Chang D, Zhu P, Milliard RW, et al: MicroRNA-377 regulates angiogenesis by targeting vEGF: Implications for mesenchymal stem cells based therapy in ischemic heart disease. Circulation. 128. 2013
12	Li N, Liu Q, Su Q, Wei C, Lan B, Wang J, Bao G, Yan F, Yu Y, Peng B, et al: Effects of legumain as a potential prognostic factor on gastric cancers. Med Oncol. 30:6212013. View Article : Google Scholar : PubMed/NCBI
13	Orditura M, Galizia G, Sforza V, Gambardella V, Fabozzi A, Laterza MM, Andreozzi F, Ventriglia J, Savastano B, Mabilia A, et al: Treatment of gastric cancer. World J Gastroenterol. 20:1635–1649. 2014. View Article : Google Scholar : PubMed/NCBI
14	Vicentini C, Fassan M, D’Angelo E, Corbo V, Silvestris N, Nuovo GJ and Scarpa A: Clinical application of microRNA testing in neuroendocrine tumors of the gastrointestinal tract. Molecules. 19:2458–2468. 2014. View Article : Google Scholar : PubMed/NCBI
15	Beckman JD, Chen C, Nguyen J, Thayanithy V, Subramanian V, Steer CJ and Vercellotti GM: Regulation of heme oxygenase-1 protein expression by miR-377 in combination with miR-217. J Biol Chem. 286:3194–3202. 2011. View Article : Google Scholar :
16	Zhang R, Luo H, Wang S, Chen W, Chen Z, Wang HW, Chen Y, Yang J, Zhang X, Wu W, et al: MicroRNA-377 inhibited prolife ration and invasion of human glioblastoma cells by directly targeting specificity protein 1. Neuro Oncol. 16:1510–1522. 2014. View Article : Google Scholar : PubMed/NCBI
17	Tsirimonaki E, Fedonidis C, Pneumaticos SG, Tragas AA, Michalopoulos I and Mangoura D: PKCε signalling activates ERK1/2, and regulates aggrecan, ADAMTs5, and miR377 gene expression in human nucleus pulposus cells. PLoS One. 8:e820452013. View Article : Google Scholar
18	Bertoli C, Skotheim JM and de Bruin RAM: Control of cell cycle transcription during G1 and S phases. Nat Rev Mol Cell Biol. 14:518–528. 2013. View Article : Google Scholar : PubMed/NCBI
19	Duffy MJ, Synnott NC, McGowan PM, Crown J, O’Connor D and Gallagher WM: p53 as a target for the treatment of cancer. Cancer Treat Rev. 40:1153–1160. 2014. View Article : Google Scholar : PubMed/NCBI
20	Shetzer Y, Solomon H, Koifman G, Molchadsky A, Horesh S and Rotter V: The paradigm of mutant p53-expressing cancer stem cells and drug resistance. Carcinogenesis. 35:1196–1208. 2014. View Article : Google Scholar : PubMed/NCBI
21	Kubota E, Williamson CT, Ye R, Elegbede A, Peterson L, Lees-Miller SP and Bebb DG: Low ATM protein expression and depletion of p53 correlates with olaparib sensitivity in gastric cancer cell lines. Cell Cycle. 13:2129–2137. 2014. View Article : Google Scholar : PubMed/NCBI
22	Song MS, Salmena L and Pandolfi PP: The functions and regulation of the PTEN tumour suppressor. Nat Rev Mol Cell Biol. 13:283–296. 2012.PubMed/NCBI
23	Hollander MC, Blumenthal GM and Dennis PA: PTEN loss in the continuum of common cancers, rare syndromes and mouse models. Nat Rev Cancer. 11:289–301. 2011. View Article : Google Scholar : PubMed/NCBI
24	Carnero A, Blanco-Aparicio C, Renner O, Link W and Leal JFM: The PTEN/PI3K/AKT signalling pathway in cancer, therapeutic implications. Curr Cancer Drug Targets. 8:187–198. 2008. View Article : Google Scholar : PubMed/NCBI
25	Bjerre C, Vinther L, Belling KC, Würtz SØ, Yadav R, Lademann U, Rigina O, Do KN, Ditzel HJ, Lykkesfeldt AE, et al: TIMP1 overexpression mediates resistance of MCF-7 human breast cancer cells to fulvestrant and down-regulates progesterone receptor expression. Tumour Biol. 34:3839–3851. 2013. View Article : Google Scholar : PubMed/NCBI
26	Lu YC, Chang JT, Liao CT, Kang CJ, Huang SF, Chen IH, Huang CC, Huang YC, Chen WH, Tsai CY, et al: OncomiR-196 promotes an invasive phenotype in oral cancer through the NME4-JNK-TIMP1-MMP signaling pathway. Mol Cancer. 13:2182014. View Article : Google Scholar : PubMed/NCBI
27	Bunatova K, Pesta M, Kulda V, Topolcan O, Vrzalova J, Sutnar A, Treska V, Pecen L and Liska V: Plasma TIMP1 level is a prognostic factor in patients with liver metastases. Anticancer Res. 32:4601–4606. 2012.PubMed/NCBI